Published in Mediators Inflamm on June 01, 2003
Imbalance in the production between vascular endothelial growth factor and endostatin in Kawasaki disease. Clin Exp Immunol (2005) 0.88
Circulating sCD138 and some angiogenesis-involved cytokines help to anticipate the disease progression of early-stage B-cell chronic lymphocytic leukemia. Mediators Inflamm (2006) 0.85
Circulating levels of angiogenic cytokines in advanced breast cancer patients with system chemotherapy and their potential value in monitoring disease course. J Cancer Res Clin Oncol (2010) 0.76
Elevated serum endostatin levels is associated with favorable outcome in acute myeloid leukemia. Indian J Hematol Blood Transfus (2008) 0.75
Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell (1997) 13.94
National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood (1996) 13.35
Clinical staging of chronic lymphocytic leukemia. Blood (1975) 7.29
Transforming growth factor-beta: vasculogenesis, angiogenesis, and vessel wall integrity. Cytokine Growth Factor Rev (1997) 3.11
Vascular endothelial growth factor is induced in response to transforming growth factor-beta in fibroblastic and epithelial cells. J Biol Chem (1994) 2.87
Increased angiogenesis in the bone marrow of patients with acute myeloid leukemia. Blood (2000) 2.48
Clinical implications of circulating angiogenic factors in cancer patients. J Clin Oncol (2001) 2.15
Spectrum of tumor angiogenesis in the bone marrow of children with acute lymphoblastic leukemia. Am J Pathol (1997) 1.98
Angiogenic growth factors and endostatin in non-Hodgkin's lymphoma. Br J Haematol (1999) 1.77
Increased bone marrow angiogenesis in B cell chronic lymphocytic leukemia. Leukemia (2000) 1.46
B-CLL cells are capable of synthesis and secretion of both pro- and anti-angiogenic molecules. Leukemia (2002) 1.32
Transforming growth factor beta as endogenous growth inhibitor of chronic lymphocytic leukemia B cells. J Exp Med (1994) 1.28
Serum endostatin levels are elevated in patients with soft tissue sarcoma. Cancer (2001) 1.18
Imbalance in production between vascular endothelial growth factor and endostatin in patients with rheumatoid arthritis. J Rheumatol (2000) 1.15
In vitro and in vivo production of vascular endothelial growth factor by chronic lymphocytic leukemia cells. Blood (2000) 1.11
Elevated serum levels of transforming growth factor beta1 in Epstein-Barr virus-associated nasopharyngeal carcinoma patients. Int J Cancer (1999) 1.07
A high pretreatment serum basic fibroblast growth factor concentration is an independent predictor of poor prognosis in non-Hodgkin's lymphoma. Blood (1999) 1.00
Chronic lymphocytic leukemia B cells are resistant to the apoptotic effects of transforming growth factor-beta. Blood (1997) 0.99
Loss of functional cell surface transforming growth factor beta (TGF-beta) type 1 receptor correlates with insensitivity to TGF-beta in chronic lymphocytic leukemia. Proc Natl Acad Sci U S A (1997) 0.92
Serum endostatin levels are elevated and correlate with serum vascular endothelial growth factor levels in patients with stage IV clear cell renal cancer. Clin Cancer Res (2000) 0.91
Circulating angiogenesis inhibitor endostatin and positive endothelial growth regulators in patients with systemic lupus erythematosus. Lupus (2002) 0.90
Clinicoprognostic implications of increased serum levels of vascular endothelial growth factor and basic fibroblastic growth factor in early B-cell chronic lymphocytic leukaemia. Br J Cancer (2002) 0.89
B-cell chronic lymphocytic leukaemia cells express and release transforming growth factor-beta. Br J Haematol (1992) 0.88
Angiogenesis in B-cell chronic lymphocytic leukemia: methods of study, clinical significance and prognostic implications. Leuk Lymphoma (2001) 0.86
Serum endostatin levels in patients with hepatocellular carcinoma. Ann Oncol (2000) 0.85
Bone marrow angiogenesis in patients achieving complete response after stem cell transplantation for multiple myeloma. Leukemia (1999) 0.84
The thin red line: angiogenesis in normal and malignant hematopoiesis. Exp Hematol (2000) 0.83
Angiogenesis in B-chronic lymphocytic leukemia. Leuk Res (2001) 0.82
Heterogenous response of B lymphocytes to transforming growth factor-beta in B-cell chronic lymphocytic leukaemia: correlation with the expression of TGF-beta receptors. Br J Haematol (1997) 0.82
Cladribine decreases the level of angiogenic factors in patients with chronic lymphocytic leukemia. Neoplasma (2002) 0.82
Autocrine transforming growth factor-beta from chronic lymphocytic leukemia-B cells interferes with proliferative T cell signals. Immunobiology (1999) 0.80
Increased intracellular and plasma levels of basic fibroblast growth factor in B-cell chronic lymphocytic leukemia. Blood (1995) 0.80
Serum transforming growth factor-beta1 in patients with renal cell carcinoma. J Urol (1997) 0.80
Serum concentrations of endostatin in patients with vulvar cancer. Gynecol Oncol (1999) 0.78
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. N Engl J Med (2014) 6.73
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia. N Engl J Med (2015) 5.69
Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study. Lancet Oncol (2011) 5.67
Alemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukemia. J Clin Oncol (2007) 4.93
Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia. J Clin Oncol (2010) 4.79
Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION). Blood (2011) 3.71
Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression. J Clin Oncol (2007) 3.54
Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia after failure of first-line imatinib: a randomized phase 2 trial. Blood (2007) 3.15
Final results from a multicenter, international, pivotal study of romidepsin in refractory cutaneous T-cell lymphoma. J Clin Oncol (2010) 2.33
First clinical use of ofatumumab, a novel fully human anti-CD20 monoclonal antibody in relapsed or refractory follicular lymphoma: results of a phase 1/2 trial. Blood (2008) 2.17
Phase I trial of anti-CD22 recombinant immunotoxin moxetumomab pasudotox (CAT-8015 or HA22) in patients with hairy cell leukemia. J Clin Oncol (2012) 2.15
Cladribine, but not fludarabine, added to daunorubicin and cytarabine during induction prolongs survival of patients with acute myeloid leukemia: a multicenter, randomized phase III study. J Clin Oncol (2012) 1.56
Evaluation of circulating endothelial cells as noninvasive marker of angiogenesis in patients with chronic lymphocytic leukemia. Leuk Lymphoma (2009) 1.44
Intracoronary administration of stem cells in patients with acute myocardial infarction - angiographic follow-up. Kardiol Pol (2009) 1.42
Cytotoxic effect of R-etodolac (SDX-101) in combination with purine analogs or monoclonal antibodies on ex vivo B-cell chronic lymphocytic leukemia cells. Leuk Lymphoma (2006) 1.42
Targeted drugs in chronic myeloid leukemia. Curr Med Chem (2008) 1.25
Functional C3435T polymorphism of MDR1 gene: an impact on genetic susceptibility and clinical outcome of childhood acute lymphoblastic leukemia. Eur J Haematol (2004) 1.25
The mammalian target of the rapamycin (mTOR) kinase pathway: its role in tumourigenesis and targeted antitumour therapy. Cell Mol Biol Lett (2005) 1.22
Skin lesions in chronic lymphocytic leukemia. Leuk Lymphoma (2007) 1.19
Human leukocyte antigens class II and tumor necrosis factor genetic polymorphisms are independent predictors of non-Hodgkin lymphoma outcome. Blood (2002) 1.18
Pharmacogenomics of MDR1/ABCB1 gene: the influence on risk and clinical outcome of haematological malignancies. Hematology (2004) 1.14
Elevated IL-10 plasma levels correlate with poor prognosis in diffuse large B-cell lymphoma. Eur Cytokine Netw (2006) 1.09
The number and distribution of blood dendritic cells in the epidermis and dermis of healthy human subjects. Folia Histochem Cytobiol (2006) 1.03
Expression and prognostic significance of the inhibitor of apoptosis protein (IAP) family and its antagonists in chronic lymphocytic leukaemia. Eur J Cancer (2010) 1.03
Effect of intracoronary injection of mononuclear bone marrow stem cells on left ventricular function in patients with acute myocardial infarction. Am J Cardiol (2009) 1.01
Toll-like receptors and their role in carcinogenesis and anti-tumor treatment. Cell Mol Biol Lett (2008) 1.00
Vascular endothelial growth factor and its soluble receptors VEGFR-1 and VEGFR-2 in the serum of patients with systemic lupus erythematosus. Mediators Inflamm (2003) 1.00
Comparison of cladribine plus cyclophosphamide with fludarabine plus cyclophosphamide as first-line therapy for chronic lymphocytic leukemia: a phase III randomized study by the Polish Adult Leukemia Group (PALG-CLL3 Study). J Clin Oncol (2010) 0.99
Common genetic variation at 15q25.2 impacts on chronic lymphocytic leukaemia risk. Br J Haematol (2011) 0.97
Population pharmacokinetics of rituximab in patients with chronic lymphocytic leukemia. J Clin Pharmacol (2012) 0.96
Inactivation of TP53 correlates with disease progression and low miR-34a expression in previously treated chronic lymphocytic leukemia patients. Blood (2013) 0.95
Older and new purine nucleoside analogs for patients with acute leukemias. Cancer Treat Rev (2013) 0.95
Plasma TNF-alpha and IL-10 level-based prognostic model predicts outcome of patients with diffuse large B-Cell lymphoma in different risk groups defined by the International Prognostic Index. Arch Immunol Ther Exp (Warsz) (2010) 0.94
Effect of FCGR2A and FCGR3A variants on CLL outcome. Blood (2010) 0.93
A phase 2, randomized, double-blind, placebo-controlled study of siltuximab (anti-IL-6 mAb) and bortezomib versus bortezomib alone in patients with relapsed or refractory multiple myeloma. Am J Hematol (2015) 0.92
Circulating VEGF and its soluble receptors sVEGFR-1 and sVEGFR-2 in patients with acute leukemia. Eur Cytokine Netw (2003) 0.91
Relationship between peripheral blood dendritic cells and cytokines involved in the pathogenesis of systemic lupus erythematosus. Eur Cytokine Netw (2004) 0.91
In vitro cytotoxic effect of proteasome inhibitor bortezomib in combination with purine nucleoside analogues on chronic lymphocytic leukaemia cells. Eur J Haematol (2005) 0.90
MDR1 (ABCB1) gene polymorphism C3435T is associated with P-glycoprotein activity in B-cell chronic lymphocytic leukemia. Pharmacol Rep (2006) 0.90
The role of non-steroidal anti-inflammatory drugs in the risk of development and treatment of hematologic malignancies. Leuk Lymphoma (2008) 0.90
The distribution of peripheral blood dendritic cells assayed by a new panel of anti-BDCA monoclonal antibodies in healthy representatives of the polish population. Cell Mol Biol Lett (2004) 0.89
Anthracyclines potentiate activity against murine leukemias L1210 and P388 in vivo and in vitro. Eur J Haematol (2002) 0.89
Merkel cell carcinoma in a patient with B-cell chronic lymphocytic leukemia treated with cladribine and rituximab. Leuk Lymphoma (2005) 0.88
Proapoptotic activity of alemtuzumab alone and in combination with rituximab or purine nucleoside analogues in chronic lymphocytic leukemia cells. Leuk Lymphoma (2005) 0.88
Monoclonal antibodies in the treatment of systemic lupus erythematosus. Curr Drug Targets (2009) 0.88
Impact of intracoronary injection of mononuclear bone marrow cells in acute myocardial infarction on left ventricular perfusion and function: a 6-month follow-up gated 99mTc-MIBI single-photon emission computed tomography study. Eur J Nucl Med Mol Imaging (2008) 0.87
Depsipeptide (FK228) as a novel histone deacetylase inhibitor: mechanism of action and anticancer activity. Mini Rev Med Chem (2007) 0.87
Pharmacokinetics and pharmacokinetic/pharmacodynamic associations of ofatumumab, a human monoclonal CD20 antibody, in patients with relapsed or refractory chronic lymphocytic leukaemia: a phase 1-2 study. Br J Haematol (2010) 0.87
Rapamycin, the mTOR kinase inhibitor, sensitizes acute myeloid leukemia cells, HL-60 cells, to the cytotoxic effect of arabinozide cytarabine. Anticancer Drugs (2009) 0.87
Clinically meaningful reduction in pruritus in patients with cutaneous T-cell lymphoma treated with romidepsin. Leuk Lymphoma (2012) 0.86
Toll-like receptors and their role in hematologic malignancies. Curr Mol Med (2009) 0.86
Circulating vascular endothelial growth factor (VEGF) and its soluble receptors in patients with chronic lymphocytic leukemia. Eur Cytokine Netw (2005) 0.86
Clonal evolution in CLL patients as detected by FISH versus chromosome banding analysis, and its clinical significance. Eur J Haematol (2013) 0.86
Pegylated liposomal doxorubicin plus bortezomib in relapsed or refractory multiple myeloma: efficacy and safety in patients with renal function impairment. Clin Lymphoma Myeloma (2008) 0.85
Richter syndrome in chronic lymphocytic leukemia: updates on biology, clinical features and therapy. Leuk Lymphoma (2015) 0.85
Successful treatment of refractory autoimmune thrombocytopenia with rituximab and cyclosporin A in a patient with chronic granulomatous disease. Ann Hematol (2005) 0.84
Thalidomide versus dexamethasone for the treatment of relapsed and/or refractory multiple myeloma: results from OPTIMUM, a randomized trial. Haematologica (2011) 0.84
Proinflammatory interferon-gamma--inducing monokines (interleukin-12, interleukin-18, interleukin-15)--serum profile in patients with systemic lupus erythematosus. Eur Cytokine Netw (2002) 0.83
The influence of farnesyl protein transferase inhibitor R115777 (Zarnestra) alone and in combination with purine nucleoside analogs on acute myeloid leukemia progenitors in vitro. Eur J Haematol (2004) 0.83
Circulating proangiogenic molecules PIGF, SDF-1 and sVCAM-1 in patients with systemic lupus erythematosus. Eur Cytokine Netw (2007) 0.83
Influence of high expression of Smac/DIABLO protein on the clinical outcome in acute myeloid leukemia patients. Leuk Res (2010) 0.83
Hypomethylating agents in the treatment of myelodysplastic syndromes and myeloid leukemia. Curr Cancer Drug Targets (2011) 0.83
In vitro sensitivity of B-cell chronic lymphocytic leukemia to cladribine and its combinations with mafosfamide and/or mitoxantrone. Oncol Rep (2006) 0.82
Circulating endothelial cells in patients with acute myeloid leukemia. Eur J Haematol (2005) 0.82
Forodesine (BCX-1777, Immucillin H)--a new purine nucleoside analogue: mechanism of action and potential clinical application. Mini Rev Med Chem (2007) 0.81
The emerging therapeutic role of antibody mixtures. Expert Opin Biol Ther (2013) 0.81
Polymorphisms of TNF and IL-10 genes and clinical outcome of patients with chronic lymphocytic leukemia. Genes Chromosomes Cancer (2012) 0.81
Polymorphisms and haplotypes in the multidrug resistance 1 gene (MDR1/ABCB1) and risk of multiple myeloma. Leuk Res (2008) 0.81
Distribution of allelic variants of functional C3435T polymorphism of drug transporter MDR1 gene in a sample of Polish population. Pol J Pharmacol (2003) 0.81
Rituximab followed by cladribine in the treatment of heavily pretreated patients with indolent lymphoid malignancies. Leuk Lymphoma (2004) 0.81
Circulating endothelial microparticles in patients with acute myocardial infarction. Kardiol Pol (2005) 0.81
Circulating endothelial cell kinetics and their potential predictive value during mobilization procedure. J Clin Apher (2013) 0.80
Mechanisms of action of the anti-VEGF monoclonal antibody bevacizumab on chronic lymphocytic leukemia cells. Postepy Hig Med Dosw (Online) (2013) 0.80
Effects of Toll-like receptor 7 and Toll-like receptor 9 signaling stimulators and inhibitors on chronic lymphocytic leukemia cells ex vivo and their interactions with cladribine. Leuk Lymphoma (2012) 0.80
[The role of HLA DRB1 genetic polymorphisms in non-Hodgkin's lymphomas]. Przegl Lek (2005) 0.80
Novel purine nucleoside analogues for hematological malignancies. Recent Pat Anticancer Drug Discov (2008) 0.80
R-roscovitine (Seliciclib) affects CLL cells more strongly than combinations of fludarabine or cladribine with cyclophosphamide: Inhibition of CDK7 sensitizes leukemic cells to caspase-dependent apoptosis. J Cell Biochem (2010) 0.80
[The role of genetic polymorphisms within tumor necrosis factor promoter gene in non-Hodgkin's lymphomas]. Przegl Lek (2005) 0.80
Circulating angiogenic cytokines in multiple myeloma and related disorders. Eur Cytokine Netw (2003) 0.80
Inhibited apoptosis of synovial fluid lymphocytes in children with juvenile idiopathic arthritis is associated with increased expression of myeloid cell leukemia 1 and XIAP proteins. J Rheumatol (2006) 0.80
Peripheral blood lymphocyte apoptosis and circulating dendritic cells in patients with systemic lupus erythematosus: correlation with immunological status and disease-related symptoms. Clin Rheumatol (2006) 0.80
High activity of rituximab combined with cladribine and cyclophosphamide in a patient with pulmonary lymphomatoid granulomatosis and bone marrow involvement. Leuk Lymphoma (2006) 0.79
CD38 gene polymorphisms contribute to genetic susceptibility to B-cell chronic lymphocytic leukemia: evidence from two case-control studies in Polish Caucasians. Cancer Epidemiol Biomarkers Prev (2009) 0.79
Human leukocyte antigens HLA DRB1 influence clinical outcome of chronic lymphocytic leukemia? Haematologica (2007) 0.79
Multi-drug transporter MDR1 gene polymorphism and prognosis in adult acute lymphoblastic leukemia. Pharmacol Rep (2005) 0.79